 |
- Seegene to showcase a conceptual video introducing CURECA™ at ESCMID Global 2025 — a full automation system expected to cover the entire PCR workforce, from sample pre-processing to result analysis.
- Designed for 24-hour, seven-days-a-week, unattended, CURECAâ„¢ reflects the company's mission to set a new global standard and advance its vision of "a world free from all diseases."
SEOUL, South Korea, April 9, 2025 /PRNewswire/ -- Seegene Inc., a global leader in molecular diagnostics (MDx), is advancing its vision for innovation in laboratory automation with the development of CURECA™ — a next-generation system currently under development, designed to streamline automation in Polymerase Chain Reaction (PCR) testing and laboratory environments.
The company announced today that it will showcase a conceptual video introducing the CURECAâ„¢ system at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025), held April 11-15 in Vienna, Austria. The video will outline the system's design goals and envisioned workflow. A physical demonstration of the system is expected to take place in July 2025 at the Association for Diagnostics & Laboratory Medicine (ADLM 2025) in Chicago.
CURECA™ — short for Continuous Unlimited Random access Expandable and Customizable full Automation — is Seegene's envisioned PCR testing solution, intended to enable full automation of the PCR testing workflow. The system is expected to include two core components: the Customizable Pre-treatment System (CPS), responsible for sample loading and pre-treatment processing; and Customizable and Expandable Full Automation (CEFA), which would carry out sample loading and preparation for nucleic acid extraction, PCR setup, gene amplification, and result analysis.
Pioneering Full Automation of PCR Pre-treatment Processing
The pre-treatment stage in MDx requires careful handling of various specimen types — such as stool, urine, blood, and sputum — as well as sorting different container formats. Traditionally, this process has relied heavily on manual labor by trained laboratory professionals.
Seegene aims to lead innovation in automating pre-treatment processing for all PCR specimen types through the development of CPS. The system is designed to automate key steps such as sample sorting, centrifugation, vortexing and heat treatment. CPS may also operate independently of the full CURECA™ system and be applied to other laboratory testing areas such as hematology, biochemistry, and immunodiagnostics — broadening its potential utility in clinical laboratory workflows.
The modular design of CURECAâ„¢ is intended to provide laboratories with flexibility to configure the system according to their operational needs. By supporting automation across the full workflow, the system aims to help reduce the risk of human error and enable continuous, high-throughput PCR testing 24 hours a day, seven days a week.
At ESCMID Global 2025, Seegene will present a conceptual video simulating the full PCR automation workflow — from sample loading and pre-treatment processing to nucleic acid extraction, PCR setup, gene amplification, and result analysis. The presentation will further highlight the system's adaptability across different laboratory environments and testing capacities.
CURECAâ„¢ to Support Seegene's Vision of "a World Free from All Diseases"
"Until now, there has been no system capable of fully automating pre-treatment processing for all specimen types, which has prevented true automation in MDx," said Dr. Jong-Yoon Chun, founder and CEO of Seegene. "We aim to define a new global benchmark and help reshape the future of MDx."
Dr. Chun also noted that CURECAâ„¢ is envisioned to support Seegene's global technology-sharing initiative, which aims to make advanced MDx more accessible and better integrated into everyday healthcare around the world. "CURECAâ„¢ marks an early step toward advancing Seegene's vision of creating 'a world free from all diseases.' We will continue to lead through innovation and global collaboration to drive this vision ahead."
Seegene to Highlight "Redefining MDx" at ESCMID 2025
Seegene will present its syndromic real-time PCR assay portfolio under the theme "Redefining MDx" at ESCMID Global 2025, including validated testing solutions currently in use. The company will also host symposium sessions during the conference, exploring the evolving role of MDx in addressing antimicrobial resistance (AMR) and shifting diagnostic needs in the post-COVID-19 era. Featured assays, such as Drug Resistance (Entero DR) and Sexually Transmitted Infection–Antimicrobial Resistance (STI-AMR), are designed to support more informed and timely treatment decisions.
About Seegene
Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar symptoms in a single tube with quantitative information.
Visit: Seegene.com and follow linkedin.com/company/seegene-inc
Technology-sharing Initiative
The technology-sharing initiative aims to globally share Seegene's advanced diagnostic and data analysis technologies, including syndromic real-time PCR and an automated product development system (SGDDS), with a leading company partnered in each country. Partnering companies will collaborate with local scientists and experts to develop diagnostic tests tailored to the needs of their communities and fields, spanning a wide range of human and non-human diseases. The initiative's ultimate vision is to create "a world free from diseases"— a future where people no longer suffer from infectious diseases and cancer, and where animals and plants thrive without illness.
- Seegene to showcase a conceptual video introducing CURECA™ at ESCMID Global 2025 — a full automation system expected to cover the entire PCR workforce, from sample pre-processing to result analysis.
- Designed for 24-hour, seven-days-a-week, unattended, CURECAâ„¢ reflects the company's mission to set a new global standard and advance its vision of "a world free from all diseases."
SEOUL, South Korea, April 9, 2025 /PRNewswire/ -- Seegene Inc., a global leader in molecular diagnostics (MDx), is advancing its vision for innovation in laboratory automation with the development of CURECA™ — a next-generation system currently under development, designed to streamline automation in Polymerase Chain Reaction (PCR) testing and laboratory environments.
The company announced today that it will showcase a conceptual video introducing the CURECAâ„¢ system at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025), held April 11-15 in Vienna, Austria. The video will outline the system's design goals and envisioned workflow. A physical demonstration of the system is expected to take place in July 2025 at the Association for Diagnostics & Laboratory Medicine (ADLM 2025) in Chicago.
CURECA™ — short for Continuous Unlimited Random access Expandable and Customizable full Automation — is Seegene's envisioned PCR testing solution, intended to enable full automation of the PCR testing workflow. The system is expected to include two core components: the Customizable Pre-treatment System (CPS), responsible for sample loading and pre-treatment processing; and Customizable and Expandable Full Automation (CEFA), which would carry out sample loading and preparation for nucleic acid extraction, PCR setup, gene amplification, and result analysis.
Pioneering Full Automation of PCR Pre-treatment Processing
The pre-treatment stage in MDx requires careful handling of various specimen types — such as stool, urine, blood, and sputum — as well as sorting different container formats. Traditionally, this process has relied heavily on manual labor by trained laboratory professionals.
Seegene aims to lead innovation in automating pre-treatment processing for all PCR specimen types through the development of CPS. The system is designed to automate key steps such as sample sorting, centrifugation, vortexing and heat treatment. CPS may also operate independently of the full CURECA™ system and be applied to other laboratory testing areas such as hematology, biochemistry, and immunodiagnostics — broadening its potential utility in clinical laboratory workflows.
The modular design of CURECAâ„¢ is intended to provide laboratories with flexibility to configure the system according to their operational needs. By supporting automation across the full workflow, the system aims to help reduce the risk of human error and enable continuous, high-throughput PCR testing 24 hours a day, seven days a week.
At ESCMID Global 2025, Seegene will present a conceptual video simulating the full PCR automation workflow — from sample loading and pre-treatment processing to nucleic acid extraction, PCR setup, gene amplification, and result analysis. The presentation will further highlight the system's adaptability across different laboratory environments and testing capacities.
CURECAâ„¢ to Support Seegene's Vision of "a World Free from All Diseases"
"Until now, there has been no system capable of fully automating pre-treatment processing for all specimen types, which has prevented true automation in MDx," said Dr. Jong-Yoon Chun, founder and CEO of Seegene. "We aim to define a new global benchmark and help reshape the future of MDx."
Dr. Chun also noted that CURECAâ„¢ is envisioned to support Seegene's global technology-sharing initiative, which aims to make advanced MDx more accessible and better integrated into everyday healthcare around the world. "CURECAâ„¢ marks an early step toward advancing Seegene's vision of creating 'a world free from all diseases.' We will continue to lead through innovation and global collaboration to drive this vision ahead."
Seegene to Highlight "Redefining MDx" at ESCMID 2025
Seegene will present its syndromic real-time PCR assay portfolio under the theme "Redefining MDx" at ESCMID Global 2025, including validated testing solutions currently in use. The company will also host symposium sessions during the conference, exploring the evolving role of MDx in addressing antimicrobial resistance (AMR) and shifting diagnostic needs in the post-COVID-19 era. Featured assays, such as Drug Resistance (Entero DR) and Sexually Transmitted Infection–Antimicrobial Resistance (STI-AMR), are designed to support more informed and timely treatment decisions.
About Seegene
Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar symptoms in a single tube with quantitative information.
Visit: Seegene.com and follow linkedin.com/company/seegene-inc
Technology-sharing Initiative
The technology-sharing initiative aims to globally share Seegene's advanced diagnostic and data analysis technologies, including syndromic real-time PCR and an automated product development system (SGDDS), with a leading company partnered in each country. Partnering companies will collaborate with local scientists and experts to develop diagnostic tests tailored to the needs of their communities and fields, spanning a wide range of human and non-human diseases. The initiative's ultimate vision is to create "a world free from diseases"— a future where people no longer suffer from infectious diseases and cancer, and where animals and plants thrive without illness.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Seegene Announces Development of CURECA™, a Next-Generation Fully Automated PCR Solution Featuring Customizable Pre-treatment Automation
LONDON, Dec. 20, 2025 /PRNewswire/ -- This week at London's Royal Society, board members of the world-leading science and music festival STARMUS—Garik Israelian, Sir Brian May, Peter Gabriel, Lord Michael Hintze, and Lord Martin Rees—were joined by members of Jane Goodall's family and Mary Lewis, Vice President of the Jane Goodall Institute, to announce STARMUS VIII and the launch of the Jane Goodall Earth Medal.
The medal will be awarded for the first time at STARMUS VIII, to be hosted in Tenerife and La Palma in 2026.
The announcement took place exactly ten years after STARMUS and Professor Stephen Hawking stood together at the Royal Society to launch the Stephen Hawking Medal for Science Communication, marking a decade of STARMUS's commitment to uniting science, art, and humanity.
STARMUS Director and Co-Founder Garik Israelian said:
"Ten years ago, Stephen Hawking joined us to launch a medal that inspired millions to look to the stars. Today, with the blessing of Jane Goodall and her family, we launch a medal that calls us to protect the Earth. STARMUS VIII will unite these two visions — the cosmic and the planetary — in a festival dedicated to the search for truth."
Stephen Hawking once said of STARMUS:
"In a world beset by so many terrible problems, STARMUS offers a ray of hope… a unique debating chamber for the future of the human race."
In 2026, STARMUS will celebrate the 10th anniversary of the Stephen Hawking Medal, honoring a decade of scientists, creators, musicians, filmmakers, and communicators who have carried forward Hawking's vision—encouraging humanity to question deeply and embrace the power of science.
At the same time, the festival will award the inaugural STARMUS Jane Goodall Earth Medal, a global honor recognizing voices who protect the planet, defend biodiversity, and redefine humanity's relationship with nature. Approved and blessed by Dr. Jane Goodall, DBE, and her family, the medal extends the STARMUS mission into environmental and humanitarian action.
Jane Goodall held a cherished role within STARMUS as an Advisory Board Member, Hawking Medal laureate, keynote speaker, and a source of inspiration—particularly for the people of La Palma following the volcanic eruption. In private conversations with Israelian and Mary Lewis, she gave her blessing for an environmental and humanitarian medal to bear her name.
Merlin Van-Lawick, Jane Goodall's grandson, said:
"We are deeply grateful that STARMUS chose to honor my grandmother in this way. We fully support this initiative, and Jane has given it her blessing."
STARMUS Co-Founder Sir Brian May added:
"Jane Goodall and Stephen Hawking changed how we see the world — one by looking to the stars, the other by reminding us to protect life on Earth. Bringing their legacies together is profoundly necessary for our time."
www.starmus.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
BRIAN MAY AND STARMUS MARK 10 YEARS OF THE STEPHEN HAWKING SCIENCE MEDAL WITH THE LAUNCH OF THE JANE GOODALL EARTH MEDAL
BRIAN MAY AND STARMUS MARK 10 YEARS OF THE STEPHEN HAWKING SCIENCE MEDAL WITH THE LAUNCH OF THE JANE GOODALL EARTH MEDAL
